SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2)
GLOBAL PHARMACEUTICAL CORPORATION
------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
__________________________________________________________________
(Title of Class of Securities)
378922 10 8
------------------------------------------------------------------
(Cusip Number)
Klaus H. Jander, Esq.
Richard T. McDermott, Esq.
Rogers & Wells LLP
200 Park Avenue
New York, NY 10166
(212) 878-8000
------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 21, 1999
------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
13d-1(f) or 13d-1(g), check the following box |_|
Note. Schedules filed in paper format should include a signed
original and five copies of the schedule, including all exhibits. See
Rule 13d-7(b) for the other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 4 Pages)
<PAGE>
- --------------------------------- -------------------------------
CUSIP No. 378922 10 8 13D Page 2 of 4 Pages
- --------------------------------- -------------------------------
============ ===================================================================
1. NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Merck KGaA
============ ===================================================================
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)|_|
(b)|_|
============ ===================================================================
3. SEC USE ONLY
============ ===================================================================
4. SOURCES OF FUNDS
OO
============ ===================================================================
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e)
|_|
============ ===================================================================
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
- ------------------------- ------- ==============================================
7. SOLE VOTING POWER
NUMBER OF
UNITS 100,000
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
------- ==============================================
8. SHARED VOTING POWER
0
------- ==============================================
9. SOLE DISPOSITIVE POWER
100,000
------- ==============================================
10. SHARED DISPOSITIVE POWER
0
============ ===================================================================
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
100,000
============ ===================================================================
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
|-|
============ ===================================================================
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.4%
============ ===================================================================
14. TYPE OF REPORTING PERSON
CO
============ ===================================================================
<PAGE>
SCHEDULE 13D
FILED PURSUANT TO RULE 13d-1
OF THE GENERAL RULES AND REGULATIONS UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
This Amendment No. 2, which relates to shares of the common stock, par value
$0.01 per share (the "Common Stock") of Global Pharmaceuticals Corporation, a
Delaware corporation (the "Issuer") and is being filed by Merck KGaA,
supplements and amends the statement on Schedule 13D originally filed with the
Commission on February 22, 1996, as amended by Amendment No. 1 thereto, dated
March 30, 1998.
Item 4. Purpose of the Transaction.
Item 4 is amended as follows:
On June 21, 1999, Merck KGaA sold 150,000 shares of Common Stock in a brokerage
transaction at a sales price of $2-7/8 per share. The settlement date of the
sale was June 24, 1999. The 150,000 shares sold by Merck KGaA represented
approximately 2.1% of the then issued and outstanding shares of Common Stock.
Item 5. Interest in Securities of the Issuer.
Item 5 is amended as follows:
As described above in Item 4, on June 21, 1999, Merck KGaA disposed of 150,000
shares of Common Stock.
As of the date hereof, Merck KGaA is the beneficial owner of 100,000 shares of
Common Stock, representing approximately 1.4% of the issued and outstanding
shares of Common Stock.
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: July 21, 1999
MERCK KGaA
By: /s/ Klaus-Peter Brandis
Name: Klaus-Peter Brandis
Title: Senior Manager Legal Affairs
